Brian Malte, MD
Pulmonary Disease · Mountain Home, ARNPI 1669787784
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.9%), education and travel and lodging — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Intuitive Surgical at 46.7% of the total. Reporting peaked in 2024 at $7,689 and has fallen 78.8% since, to $1,633 in 2025. Among pulmonary disease clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 440 payments — averaging $32.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- GSK$1K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$635
- Boehringer Ingelheim$567
- Grifols USA, LLC$552
- plus $3K from 36 others
What the payments were for
- Speaking & faculty fees$1001%
- Travel & lodging$2,56018%
- Food & beverage$7,39452%
- Education$4,19029%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,486
- DUPIXENT$125
How this compares
$14,243 in reported general payments places this provider in the 90th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 924 | $907,307 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 45 | $432,110 |
| NucalaMepolizumab | 67 | $251,622 |
| OfevNintedanib Esylate | 15 | $192,841 |
| OpsumitMacitentan | 13 | $166,477 |
| AdempasRiociguat | 11 | $149,129 |
| Spiriva RespimatTiotropium Bromide | 180 | $145,606 |
| Fasenra PenBenralizumab | 22 | $128,247 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 140 | $121,597 |
| Breo ElliptaFluticasone/Vilanterol | 175 | $117,287 |
| SymbicortBudesonide/Formoterol Fumarate | 284 | $96,095 |
| Advair HfaFluticasone Propion/Salmeterol | 64 | $42,147 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 35 | $37,614 |
| Incruse ElliptaUmeclidinium Bromide | 77 | $33,343 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 616 | $27,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $1,311 | $1,338,6581,307 claims |
| Grifols USA, LLCProlastin C | $552 | $432,11045 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $567 | $400,358254 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,089 | $231,436442 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $213 | $166,47713 claims |
| BayerAdempas | $58 | $149,12911 claims |
| MerckDulera | $17 | $17,83035 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Mountain Home
- Ladly AbrahamConway$371K
- Daniel PaulRogers$244K
- Jason McKinneyRogers$86K
- Arturo MeadeFort Smith$67K
- Nikhil MeenaLittle Rock$63K
- Penchala MittadodlaRogers$21K
- Mark SiffordJonesboro$20K
- Zafirah SalmanNorth Little Rock$18K
- Dominika SzwedoNorth Little Rock$17K
- Hanan Khadam-MakhoulLittle Rock$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.